Xenetic Biosciences is trading at $1.70, down -8.60%, before the November 9, 2026 session; the catalyst remains unclear. - Shares compare with the $1.87 previous close. - Xenetic’s latest located release, dated November 4, concerned an upcoming ASH presentation and does not establish a cause for the decline. - Available market context shows positive futures, so broad-market weakness does not explain the move.